# Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients

> **NCT03947437** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)** · enrollment: 142 (estimated)

## Conditions studied

- Leprosy

## Interventions

- **BIOLOGICAL:** LEP-F1 + GLA-SE
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03947437
- **Lead sponsor:** The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02
- **Primary completion:** 2024-03
- **Final completion:** 2025-04
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2023-06-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03947437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03947437, "Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03947437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*